|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 5. Inhibition of spry2 alters dorsoventral patterning. (A-D) Embryos
co-injected with mo-spry2 and dn-spry2 display severely reduced bmp2b
expression. (E-L) Increased Bmp signalling levels cause alterations of DV
patterning in spry2 loss-of-function experiments. (F) Injection of mo-spry2
causes an expansion of cyp26a-expressing dorsal anterior
neurectoderm, compared with (E) wild type (wt), which is abolished by
co-injection of bmp2b (G) similar to inhibition of neural fate after
injection of bmp2b alone (H). (I,J) mo-spry2-injected embryos display
a reduction of the foxi1-expressing ventral epidermis. Co-injection
of bmp2b rescues and even enlarges the epidermal territory (K)
similar to a single bmp2b injection (L). (A-D) Shield stage; (E-L)
midgastrula stage. (A-D,E-L, top) Lateral views. (E-L, bottom) Animal pole
views; all embryos are dorsal towards the right.
|
